Literature DB >> 14769441

The role of the renin-angiotensin system in malignant vascular injury affecting the systemic and cerebral circulations.

Tara A Collidge1, G Alistair Lammie, Stewart Fleming, John J Mullins.   

Abstract

Malignant hypertension is a rare but serious syndrome complicating 1% of essential hypertension and causing neurological, renal and cardiac complications. Despite improved anti-hypertensive medication, the incidence of this condition fails to decline. In the first part of this review, we discuss transgenic rat models of malignant hypertension, generated by over-expressing renin, to illustrate the role of the renin-angiotensin system in the development of systemic hypertensive vascular remodelling and hypertension. In the second part, we focus on the cerebrovascular response to hypertension and discuss new data using a conditional, transgenic model of malignant hypertension, the inducible hypertensive rat (IHR). Cerebral infarction associates strongly with hypertension in man and the mechanisms by which hypertension predisposes to different types of stroke remains poorly understood. Rats have similar cerebrovascular anatomy and structure to humans and as such provide a good experimental tool. To date, such models lack controllability and blood-pressure matched controls. Using the IHR, we have manipulated dietary salt and water intake to generate a novel, controllable stroke phenotype. Hypertensive small-vessel stroke develops over a predictable time period, permitting the study of developing cerebrovascular lesions. Systemic end-organ injury and hypertension are not affected. Dissociation of the systemic and central vascular responses in this way, will allow for comparative study of animals with equivalent hypertension, genetic background and systemic features of hypertension with or without stroke.

Entities:  

Mesh:

Year:  2004        PMID: 14769441     DOI: 10.1016/j.pbiomolbio.2003.11.003

Source DB:  PubMed          Journal:  Prog Biophys Mol Biol        ISSN: 0079-6107            Impact factor:   3.667


  8 in total

Review 1.  Models that matter: white matter stroke models.

Authors:  Elif G Sozmen; Jason D Hinman; S Thomas Carmichael
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

Review 2.  Etiology of stroke and choice of models.

Authors:  Paul R Krafft; Emma L Bailey; Tim Lekic; William B Rolland; Orhan Altay; Jiping Tang; Joanna M Wardlaw; John H Zhang; Cathie L M Sudlow
Journal:  Int J Stroke       Date:  2012-07       Impact factor: 5.266

3.  Advances in transgenic rat production.

Authors:  Wanda E Filipiak; Thomas L Saunders
Journal:  Transgenic Res       Date:  2006-09-29       Impact factor: 2.788

4.  Hypertensive crisis in children and adolescents.

Authors:  Tomáš Seeman; Gilad Hamdani; Mark Mitsnefes
Journal:  Pediatr Nephrol       Date:  2018-10-01       Impact factor: 3.714

5.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

Review 6.  New technology for an old favorite: lentiviral transgenesis and RNAi in rats.

Authors:  Christina Tenenhaus Dann
Journal:  Transgenic Res       Date:  2007-08-08       Impact factor: 2.788

7.  CD4(+)CD25(+) T Cells in primary malignant hypertension related kidney injury.

Authors:  Hongdong Huang; Yang Luo; Yumei Liang; Xidai Long; Youming Peng; Zhihua Liu; Xiaojun Wen; Meng Jia; Ru Tian; Chengli Bai; Cui Li; Fuliang He; Qiushi Lin; Xueyan Wang; Xiaoqun Dong
Journal:  Sci Rep       Date:  2016-06-09       Impact factor: 4.379

8.  20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Lenka Sedláková; Soňa Kikerlová; Zuzana Husková; Lenka Červenková; Věra Čertíková Chábová; Josef Zicha; John R Falck; John D Imig; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Vojtěch Krátký; Luděk Červenka; Libor Kopkan
Journal:  Biosci Rep       Date:  2018-09-12       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.